Last reviewed · How we verify
Ultomiris
At a glance
| Generic name | Ultomiris |
|---|---|
| Also known as | There is no interventional drug. Ultomiris treatment is an inclusion criterion. |
| Sponsor | Alexion Pharmaceuticals, Inc. |
| Target | Complement C5 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Atypical hemolytic uremic syndrome (aHUS)
- Generalized myasthenia gravis
- Myasthenia gravis
- Paroxysmal nocturnal hemoglobinuria
Common side effects
- Upper respiratory tract infection
- Diarrhea
- Nausea
- Vomiting
- Pyrexia
- Hypertension
- Anemia
- Abdominal pain
- Fatigue
- Edema peripheral
- Headache
- Constipation
Key clinical trials
- Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant (PHASE3)
- Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
- Danicopan Early Access Program
- A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment (PHASE3)
- Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
- Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data
- Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
- Ravulizumab Outcomes in Polish Patients With aHUS
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |